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ABSTRACT
Objective To review the literature on the views of
healthcare professionals to the linkage of healthcare
data and to identify any potential barriers and/or
facilitators to participation in a data linkage system.
Methods Published papers describing the views of
healthcare professionals (HCPs) to data sharing and
linkage were identiﬁed by searches of Medline, EMBASE,
SCOPUS, CINAHL, and PsychINFO. The searches were
limited to papers published in the English language from
2001 to 2011.
Results A total of 2917 titles were screened. From
these, 18 papers describing the views of HCPs about
data linkage or data sharing of routinely collected
healthcare data at an individual patient level were
included. Views were generally positive, and potential
beneﬁts were reported. Facilitators included having trust
in the system including data governance, reliability, and
feedback. Some negative views, identiﬁed as barriers
were also expressed including costs, data governance,
technical issues, and privacy concerns. Effects on the
physician–patient relationship, and workload were also
identiﬁed as deterrent.
Discussion From the published literature included in
this review, the views of HCPs were in general positive
towards data sharing for public health purposes. The
identiﬁcation of barriers to contributing to a data linkage
system allows these to be addressed in a planned data
linkage project for pharmacovigilance. The main barriers
identiﬁed were concerns about costs, governance and
interference with the prescriber–patient relationship.
These would have to be addressed if healthcare
professionals are to support a data linkage system to
improve patient safety.
BACKGROUND AND SIGNIFICANCE
Pharmacovigilance is the process by which adverse
effects of drugs are detected, assessed, understood,
and prevented.1 However, current systems are gener-
ally considered to be suboptimal2 3 and new
approaches are required. Existing systems of pharma-
covigilance vary and may be unique to individual
countries, but often use elements of signal generation
or dedicated follow-up studies. The term ‘signal gen-
eration’ refers to strategies designed to identify
potential causal relationships between drug exposure
and an adverse event. The Yellow Card
Scheme (YCS) in the UK relies on voluntary reporting
of adverse drug reactions (ADRs) by healthcare pro-
fessionals (HCPs) and, more recently, by patients.4 In
adults, all suspected adverse reactions to newly
licensed drugs (currently bearing an inverse black tri-
angle in the British National Formulary) should be
reported.3 5 For children, any suspected adverse drug
reaction, independent of licensing status or severity
of event, should be reported.6 Although the YCS is
well established, its recognized limitations include the
voluntary nature of reporting, the lack of a denomin-
ator (the total number of exposed individuals), the
duration of therapy, and the variable quality of the
data received.7
Although pre-licensing clinical studies aim to iden-
tify possible ADRs in addition to their clinical effect-
iveness, the limited number of patients in these studies
reduces the chance of identifying uncommon reac-
tions. At licensing it is not uncommon for less than
2000 patients to have been exposed to the given drug,
whereas as many as 30 000 exposed individuals may
be required to identify an ADR with an incidence of
1:10 000.3 Establishing sufﬁciently large exposure
cohorts can be challenging, particularly for orphan
drugs or rare conditions.8 This is compounded, par-
ticularly in children, by the frequent use of off-label or
unlicensed drugs which are not subject to rigorous
post-marketing surveillance.9 Linkage at individual
patient level of routinely acquired health data between
primary and secondary care could be important10;
rates of off-label or unlicensed prescribing are higher
in secondary (hospital) care,10 11 but current systems
cannot link reactions reported to the general practi-
tioner (GP) with the original hospital prescription.
Linkage of routine healthcare datasets by unique
patient identiﬁers could provide an alternative or com-
plementary approach to the identiﬁcation of ADRs. It
would permit following exposed individuals in real
time and provide a denominator. Routine data linkage
would also enable creation of exposure cohorts in
order to monitor long-term outcomes and enable a
more efﬁcient screening for side-effects or ADRs due
to an ever increasing data pool.12 The use of routine
healthcare data in the identiﬁcation of potential
adverse reactions to medicines through signal gener-
ation as well as the investigations of associations
between an adverse reaction and medicines has been
described previously.8 13 Whole population single
databases compiled for administrative purposes such
as the Hospital Episodes Statistics (HES) in England
have demonstrated their potential in monitoring
disease trends and important health outcomes,14 and
in Sweden the use of linked national datasets for
whole population epidemiology, or what is judged to
be clinically relevant research, has been made possible
without individual patient consent by the Swedish
Health Act and European Union directive 95/46/EC.15
Although data linkage is mostly seen as advanta-
geous, in particular for pharmacovigilance,8 10 16 17
some concerns have been voiced regarding
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conﬁdentiality and data protection for patient identiﬁable
data18–20 as well as practical issues about incomplete or missing
data in routinely collected datasets.12 21 22 A Wellcome report
published in 2009 in the UK recognized the potential of the use
of electronic records for data linkage and research but also high-
lighted that clinical data can rarely be anonymous, in the full
sense of the word.23
To the best of our knowledge there is no current system
which uses routine linkage of healthcare data for the purpose of
identifying and monitoring ADRs. The CHIMES (Child
Medical Records for Safer Medicines) program in Scotland is a
research project which is developing a new system for drug
monitoring and surveillance based on a linkage of routinely col-
lected healthcare data from primary and secondary care, and
prescription data. The focus of this initiative will be on children
as it is known that ADRs in this population are particularly
under-reported. Whilst the use of anonymised data from linked
routinely collected primary and secondary care healthcare data-
sets is generally supported as long as the ethical, legal, and prac-
tical issues are taken into account,20 21 24 little is known about
the views of HCPs who are the main providers of and in some
cases the designated ‘guardians’ of such data. This information
is important because if concerns are not identiﬁed and
addressed, then HCPs would not engage in this process, redu-
cing its efﬁciency. The aim of the work reported here was to
describe the views of HCPs to data sharing or data linkage of
clinical data for research purposes.
OBJECTIVE
The objective of this literature review was to address the follow-
ing questions: (1) What are the perceived barriers and facilita-
tors to the linkage of routinely acquired healthcare data from
the perspective of HCPs? (2) Would data linkage of routinely
acquired healthcare data for clinical and research purposes be
acceptable to HCPs?
METHODS
A systematic approach was used to review the current literature
(as shown in ﬁgure 1).
Bibliographic databases and search strategy
Medline (Ovid Medline In-process and other Non-Indexed
Citations and Medline (R) 1984), EMBASE (Embase Classic and
Embase 1947), SCOPUS, CINAHL, and PsychINFO were
searched. Search terms were adjusted to match individual data-
base criteria. Each search comprised three broad domains: (i)
medical records and data linkage, (ii) different types of HCPs,
and (iii) views and opinions. The full search strategy is available
on request.
Study inclusion criteria
Peer-reviewed, empirical papers, and conference abstracts cover-
ing primary and secondary research were eligible for inclusion.
Qualitative and quantitative studies were included. The search
was restricted to papers published in English from 2001 to
2011.
HCPs eligible for inclusion were medical doctors, nurses, or
pharmacists.
Papers were included if they reported on views of HCPs on
data sharing (ie, the shared use of information about an individ-
ual patient across settings), or data linkage (ie, the secondary
use of aggregated, merged data across settings) of healthcare
data, including clinical, administrative, and prescribing informa-
tion, for example, from primary to secondary care.
Study selection
Titles and abstracts were reviewed by YH for eligibility. Full arti-
cles were retrieved for assessment or further clariﬁcation, for
example if no abstract was available.
Data collection process
A data abstraction form (available on request) was used to
record standardized information from each paper as follows:
authors, citation, design, aims and objectives of the study,
methods, setting and participants (number if provided), the type
of data linked, the purpose of data linkage/sharing, and a
summary of the key ﬁndings on barriers and facilitators.
Quality assurance
A random sample of papers was discussed at fortnightly research
team meetings to conﬁrm inclusion or exclusion decisions. A
further random selection of papers was reviewed in duplicate by
the researcher (YH) with several weeks between assessments.
Papers for which the initial reviewer (YH) was unsure about
inclusion or exclusion (n=26) were discussed with a second
member of the research team (CB). In 23 cases the second
reviewer conﬁrmed the initial decision of YH (exclusion for
n=20 papers and inclusion for n=3). For the remaining three
papers a decision was made after discussion (n=2 included,
n=1 excluded).
RESULTS
Screening and identiﬁcation of papers
The search identiﬁed 2917 unique titles for screening. Selection
of abstracts and papers is detailed in ﬁgure 1. A total of 188
abstracts were reviewed. For seven papers no abstract was avail-
able and the full paper was reviewed. One hundred and ﬁfty-six
papers were eligible for full review. Two papers were unavail-
able, that is, could not be retrieved during the review time,
leaving 154 full-text articles. Authors were contacted in six
cases to ask for further information/clariﬁcation (two authors
answered and supplied further information). Papers/abstracts
were excluded due to the following reasons: not about data
sharing/linking across settings (n=47), no views of HCPs to data
sharing/linkage (n=35), not describing empirical research
(n=28), and other reasons (n=26).
Study characteristics
An overview of the characteristics of the 18 included studies is
presented in online supplementary table S1. The majority were
conducted in the USA,26–34 followed by Canada.33 35–39 Two
studies were conducted in each of the UK38 40 and the
Netherlands,41 42 and one study in Finland.43
Many studies used surveys to explore views,28 30 32 34 36 41 43
six studies used qualitative methods such as interviews and
focus groups,27 28 35 39 41 42 and the remaining ﬁve used a
mixture of both and were classiﬁed as mixed methods
research.26 31 33 37 40
Several sampling methods were used including purpos-
ive,30 31 33 convenience,35 39 random,32 40 41 and a priori.28
Although nine papers did not explicitly state their sampling
method, it appeared from the results in four cases that a purpos-
ive/convenience sample was used29 34 37 42 and in one that an
a-priori sample was employed.36 Survey response rates ranged
from 37%38 to 77.1%,32 with a median response of 58.5%.
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Participant characteristics
The majority of participants were medical doctors working in
either primary or secondary care.26–28 30–36 40–43 Other partici-
pants had a background in nursing,26 30 public health,38 39 or
pharmacy.35 40 Some studies only acknowledged the use of ‘sta-
keholders’ who were drawn from relevant organizations, and
another did not specify the background of their participants
other than stating that they were healthcare providers.29
Data shared/linked
The extent of proposed data sharing/linkage differed widely between
studies. The majority sought to identify views to data sharing for
research,27 29–32 34 36 41 43 two on pilots of data sharing26 35 and the
remainder on hypothetical scenarios.28 33 37–40 42
The most common linkages were between laboratory and radi-
ology records,26–28 30 32 34 36 followed by patient records from
either primary or secondary care.27 31 34 37 41 Other studies
described shared medication data which included data from com-
puterized physician order entry systems, discharge summaries, pre-
scriptions, and medication lists.27 28 30–32 35 37 40 42 Three studies
did not specify the clinical data to be shared.29 38 43
Type and purpose of data sharing/linkage
One study addressed views to sharing data with patients,26 and
there was also sharing of data at an aggregate level, that is,
anonymised data, with public health agencies.29 33 38 39 The
majority of papers described data sharing (hypothetical and
real) at the individual patient level, usually between pharmacies,
and primary and secondary care, and in the USA between phar-
macies and insurance companies.27–32 34–37 40–43
Views on data sharing/linkage
Although the majority of views expressed about data sharing were
positive, there were some negative views.28–32 34 35 38–40 43 Studies
categorized as ‘undecided’ in online supplementary table S1
reported both positive and negative views which appeared to be
inﬂuenced by prior experience, as those with experience of linked
data were generally in favor and those without were generally
negative.27 33 41 A full range of views about data sharing were not
identiﬁed in two studies as their purpose was to identify potential
barriers to data sharing.36 37
The use of patient data for public health purposes was
described by four papers: Rudin et al29 described the views of
clinicians about sharing their data with public health depart-
ments, AbdelMalik et al38 discussed the need for patient-
identiﬁable data for public health and the restrictions imposed
by current legislation, and El Emam et al33 and Heidebrecht
et al39 discussed the use of data for assessing immunization
coverage. These studies showed that HCPs were positive about
data sharing for a public health purpose. Only one study found
that the view towards the secondary use of patient data would
depend on the degree of identiﬁability.33
Barriers to data sharing/linkage
The key ﬁndings of each study are summarized in online supple-
mentary table S1. A frequently mentioned barrier to data
sharing related to start-up and maintenance costs, including
remuneration for participating providers.26 27 31 32 34 38
Concerns about data governance were also common, including
data security, legal restrictions, and data quality.27–29 31–33 38 40
Technical problems such as lack of interoperability between IT
systems were also identiﬁed,29 31 37 40 42 although Paré et al37
reported that these were less of an issue for data sharing per se.
Privacy issues were cited in four studies.31 32 38 42 Consent was
seen as necessary, although this was deemed impractical to
obtain for large anonymised whole population studies in one
study,33 and as a potential barrier by a minority (19%) of parti-
cipants in another.34
Figure 1 PRISMA ﬂowchart of literature review (based on Moher et al25).
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As a group, physicians often suggested possible interference
with their patient–physician relationships,33 threats to their pro-
fessional autonomy, and a potential increase in the use of such
data for litigation.42 Participants also reported a potential for an
increased workload associated with uploading, verifying, and
updating data.26 28 34 39 43 Lack of awareness of Health
Information Exchange, that is, the use of ‘electronic movement
of health-related information among organizations according to
nationally (US) recognized standards31’ was identiﬁed as a
barrier to data sharing,28 38 as was being a ‘non-user’ of existing
infrastructures, such as electronic prescribing systems.41 The
lack of a shared vision31 or commitment from management37
and competition between healthcare providers27 were also cited
as obstacles.
Facilitators to data sharing/linkage
Several studies listed possible improvements in patient care and
safety29–31 34 35 40 as facilitators for data sharing. Rudin et al29
identiﬁed trust in the system as both a barrier and a facilitator as
concerns of physicians about the sharing of clinical data
appeared to be less in those who used linked IT based patient
information systems. El Emam et al33 identiﬁed several govern-
ance features, such as comprehensive data sharing agreements,
the use of de-identiﬁed data, and mandatory reporting, for
example public health purposes that would reassure HCPs and
facilitate support for research with linked data.
The involvement of the relevant HCPs in the development of
data sharing procedures would appear to facilitate data
sharing,28 as would perceived ownership of any given project.36
Being a current user of a data sharing system,41 having a prefer-
ence to view health records electronically,34 involvement in
quality reporting initiatives,31 or perceived improvements in
patient care associated with data sharing all acted as
facilitators.29 30 34 40
HCPs perceived data sharing as beneﬁcial, and with the
potential of reducing healthcare costs28 32 by saving clinician
time in accessing relevant patient data32 40 and providing timely
access to comprehensive whole population trends and longitu-
dinal data.39 Fontaine et al31 found that using a precursor
system, that is, introducing a ‘light’ version of the planned
system before full engagement, helped to dispel concerns of
HCPs. Other facilitators included the clinical usefulness of the
system,27 36 a well designed and easy to use interface,28 34 reli-
able system performance,30 43 and the ability to give and receive
feedback.36
DISCUSSION
Summary of evidence
Data sharing was generally supported, and particularly so if
HCPs had prior experience of its application as explicitly
described in one study which compared the differences in views
between those HCPs with and without experience in data
sharing.41 Although no study identiﬁed a solely negative stance
towards the sharing or linking of clinical data, several barriers
were identiﬁed. Set-up costs for the required hardware and
internet links along with subsequent system maintenance were
perceived to be a problem,26 27 31 34 40 41 despite the potential
for a reduction in healthcare costs overall.
Potential improvements in patient care and safety were seen
as facilitators of data sharing in contrast to lack of any perceived
usefulness and patient beneﬁts acting as deterrents for participa-
tion. Hence, system utility and performance would be keys for a
successful data sharing project as they can act as both barriers
and facilitators. The results from this review indicate that HCPs
are unlikely to support any data linkage system that is compli-
cated, time-consuming, or costly. On the other hand, if beneﬁts
could be demonstrated, for example by providing easy access to
comprehensive and longitudinal data, and particularly if the
data were able to support strategic goals, this would work as a
facilitator for data sharing. The direct involvement of HCP
‘champions’ willing to drive the project, in particular from
doctors, nurses, and pharmacists, was identiﬁed to be crucial for
success, as were willingness to co-operate, involvement, and psy-
chological ownership which led to more enthusiasm.
Limitations
This review summarizes a heterogeneous set of studies from dif-
ferent countries, with different methodologies and different
data sharing or linkage schemes. Thus, only limited generaliza-
tion and interpretation of the data is possible. Although the
quality of included papers was not formally assessed using
standard scales, when any uncertainties about the exact nature
of the study were found, authors were contacted to clarify infor-
mation about study methods, such as number of interviews con-
ducted, nature of data sharing, and clariﬁcation of participants’
characteristics.
Duplicate data extraction was not performed. However, a
random sample of both included and excluded papers (n=32)
was discussed. In addition, to facilitate conﬁdence in reliability,
a selection of papers was assessed twice by the same researcher,
several weeks apart, and outcomes in terms of paper inclusion
or data extracted were identical.
Data sharing was associated with different terms, particularly
in the USA, including electronic medical records, electronic
health records, health information exchange, and computer
information systems, often without explanation for readers
unfamiliar with the described setting. One of the terms used to
describe data sharing was ‘computerized physician/provider
order entry’ (CPOE), a term that was excluded as closer examin-
ation of the papers using this term showed that CPOE described
solely the sharing of information about a patient within a single
setting, generally between the wards and pharmacy of a single
hospital. The search strategy was not amended in order to
include new terms identiﬁed during the review, such as ‘elec-
tronic health record’ (EHR), as they were already being success-
fully identiﬁed by the original search strategy. However, this
might have led to a failure to identify all possible relevant
papers.
It was also not always clear whether electronic health records
(EHRs) were shared within a single setting, such as a single
practice or hospital or across settings, that is, record accessibility
in primary and secondary care. This level of detail was central
as the aim of the current review was to identify views of HCPs
on data sharing and linkage across health sectors to inform the
development of the CHIMES program for developing a more
efﬁcient system for pharmacovigilance. Although authors were
contacted if information within their published paper was inad-
equate for an inclusion/exclusion decision, not every author pro-
vided the requested information, which led to ﬁve papers being
excluded.
Other problems encountered were the inclusion of views
from mixed populations of HCPs, managers, and the lay public
and in which answers provided could not be attributed by popu-
lation group. This limited the validity of the results, as reported
views might have been voiced by a healthcare manager or
system administrator without a clinical background.
Hopf YM, et al. J Am Med Inform Assoc 2014;21:e6–e10. doi:10.1136/amiajnl-2012-001575 e9
Review
CONCLUSION
Most studies described the sharing of data at an individual
patient level and hence the observed views about barriers and
facilitators to data sharing concerned the sharing of patient
identiﬁable data. Identiﬁed barriers included costs, governance
issues, and a perceived interference with the prescriber/patient
relationship. Facilitators to data sharing were direct involvement
of relevant HCPs in system design and the accessibility, per-
ceived usefulness, and potential perceived beneﬁts of the system.
Beneﬁts included easy access to complete and comprehensive
patient data and the potential for improving quality of care and
patient safety. In general, the views of HCPs were positive
towards data sharing and linkage but the identiﬁed barriers will
have to be addressed in future data linkage projects to facilitate
support of healthcare professionals.
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